23andMe
23andMe Files For Bankruptcy, CEO Steps Down
Genetic testing company 23andMe has filed for Chapter 11 bankruptcy protection, and the company’s CEO Anne Wojcicki has stepped down from her position.
Business
Nasdaq plans 24-hour trading to tap into growing international demand
Nasdaq Inc. plans to introduce 24-hour trading on its flagship U.S. exchange to capitalize on growing global demand for U.S. equities.
Abril Elfi
Manhattan’s Top Federal Prosecutor Damian Williams To Resign Before Trump’s Inauguration
Manhattan’s top federal prosecutor Damian Williams is planning to resign from his post before President-elect Donald Trump is inaugurated.
9th U.S. Circuit Court of Appeals
US Supreme Court tosses case involving securities fraud suit against Facebook
The Supreme Court sidestepped a decision on whether to allow shareholders to proceed with a securities fraud lawsuit accusing Facebook of misleading investors.
Alvin Tan
Record-breaking bitcoin surges towards $90,000 on Trump boost
Bitcoin rallied to the verge of $90,000 on Tuesday, riding a wave of euphoria since the election of Donald Trump as U.S. president.
Accenture
S&P 500 notches record high as Nvidia rally continues
The benchmark S&P 500 touched a record high on Thursday, boosted by strong gains in Nvidia.
adoption
US securities regulator urges against crypto bill adoption
The U.S. securities regulator on Wednesday urged U.S. lawmakers not to adopt a bill that aims to create a new legal framework for digital currencies.
$2
Bitcoin climbs above $45,000 to 21-month peak as new year kicks off
Bitcoin galloped past $45,000 for the first time since April 2022, buoyed by optimism around the possible approval of exchange-traded spot bitcoin funds.
Ben Laidler
Bitcoin hits two-month high above $30,000 in volatile week
Bitcoin jumped on Friday above $30,000 for first time since July, taking gains for the week past 10%.
brooke mallory
SEC charges former Pfizer employee for insider trading
The U.S. Securities and Exchange Commission has now charged a former Pfizer employee with alleged insider trading after he gained 2,458% by buying out-of-the-money call options one day before the company’s Paxlovid drug announcement.